Maryalice Stetler-Stevenson, M.D., Ph.D.

Dr. Stetler-Stevenson directs the Flow Cytometry Laboratory, a clinical laboratory that provides state-of-the-art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g., antibody-based therapy), prognostication, to evaluate changing signs or symptoms (e.g., new onset of neurological symptoms in a patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Lab also provides specialized, unique protocol- mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.
1) flow cytometry
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 3S235G
Bethesda, MD 20892
Ph: 301-480-8076
stetler@mail.nih.gov
Flow Cytometric Evaluation of Biomarkers
The Flow Cytometry Laboratory is a clinical laboratory that provides state-of-the-art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g., antibody-based therapy), prognostication, to evaluate changing signs or symptoms (e.g., new onset of neurological symptoms in a patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Lab also provides specialized unique protocol mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.
Selected Publications
- Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
- Leuk. Res.. 38: 371-6, 2014. [ Journal Article ]
- J. Clin. Oncol.. 32: 475-6, 2014. [ Journal Article ]
- Blood. 123: 1281-2, 2014. [ Journal Article ]
- Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
Dr. Stetler-Stevenson received her Ph.D. and M.D. from Northwestern University Medical School, Chicago, where she also trained in anatomic pathology. She completed a fellowship in hematopathology in the Laboratory of Pathology, NCI, before becoming Chief of the Flow Cytometry Unit. Dr. Stetler-Stevenson's interests include the study of factors active in lymphomagenesis and progression in lymphoid neoplasia as well as advancing the state of the art in the field of clinical flow cytometry.
Name | Position |
---|---|
Truc Ho | Technologist (Contr.) |
Robert Honec | Technologist (Contr.) |
Catharine S. McCoy MT(ASCP)I/SI | General Supervisor, Medical Technologist |
Aaron Nelson | Postbaccalaureate Fellow |
Hao-Wei Wang M.D., Ph.D. | Assistant Research Physician |
Linda S. Weaver | Technologist |
Constance M. Yuan, M.D., Ph.D. | Associate Research Physician |